Showing results (241-250 of 261) with videos related to
Sort By:
Pageof 27
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2021
Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLCMasayuki Shirasawa, Tatsuya Yoshida, Yukiko Shimoda, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040)Tomoya Fukui, Nobuaki Mamesaya, Toshiaki Takahashi, et al.Translational Lung Cancer Research|May 13, 2024
Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysisTian Tian, Yanying Li, Juan Li, et al.Protein Science : a Publication of the Protein Society|January 30, 2009
Solution structure of the RNA binding domain in the human muscleblind-like protein 2Fahu He, Weirong Dang, Chikage Abe, et al.Lung Cancer (Amsterdam, Netherlands)|April 10, 2023
Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapyMasayuki Shirasawa, Tatsuya Yoshida, Kouya Shiraishi, et al.British Journal of Cancer|September 21, 2023
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancerMasayuki Shirasawa, Tatsuya Yoshida, Kouya Shiraishi, et al.Cancer Science|January 26, 2024
Patient survey on cancer genomic medicine in Japan under the national health insurance systemHidenori Kage, Nana Akiyama, Hyangri Chang, et al.Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencingHidenori Mizugaki, Akinobu Hamada, Tatsuhiro Shibata, et al.The Oncologist|November 28, 2019
Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 StudyKazunari Tateishi, Ryo Ko, Takehito Shukuya, et al.Translational Lung Cancer Research|September 29, 2021
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational studyAkihiro Yoshimura, Tadaaki Yamada, Yusuke Okuma, et al.Pageof 27